August 13, 2025
Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds
– Invests in 100th Portfolio Company, Celebrates 25th Year of Franchise Operation – – Announces Promotion of Lauren Flickinger and Ben Scruggs, Ph.D., as Partners – August 13, 2025 –…
August 7, 2025
HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors
Acquisition will Accelerate Global Expansion of Company’s Breakthrough Edison® Histotripsy Platform and Non-Invasive Tumor Therapy MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today…
May 23, 2025
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per…
May 7, 2025
Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma
– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support the potential of PER-001 as…
April 2, 2025
Atsena gets Bain’s support in $150M Series C to thwart blindness with gene therapy
There’s still money to be raised by gene therapy startups with good clinical data. On Wednesday, North Carolina biotech Atsena Therapeutics said it had raised a $150 million Series C…
April 2, 2025
Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow
Atsena Therapeutics' $150 million fundraise is a light of hope for the gene therapy field, which has suffered enormously in recent months. Atsena Therapeutics has raised $150 million in an…
January 13, 2025
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Strong investor syndicate backs clinical-stage Hepatitis B program while advancing pioneering gene-tuning platform DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over…
January 8, 2025
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Study AER-01-002 is using a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) patients AER-01-002 is well powered to determine if 28-days of…
August 15, 2024
HistoSonics Announces Oversubscribed $102 Million Series D Financing to Scale Launch of Non-Invasive Histotripsy Platform
Funding to Advance New Histotripsy Applications and Launch Innovative BOOMBOX Master Study HistoSonics Edison® Histotripsy System (Photo: Business Wire) August 15, 2024 08:00 AM Eastern Daylight Time MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, the…
June 25, 2024
Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes
Oversubscribed financing led by strategic investor, with participation from new and existing investors MINNEAPOLIS, June 25, 2024 /PRNewswire/ -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with…